February 25, 2016
Another record year for Bayer
Focus on the Life Sciences following the successful stock market flotation of Covestro / Substantial sales and earnings increases at HealthCare / Good business development at CropScience despite a weaker market environment / Covestro posts strong earnings improvement / Group sales increase to EUR 46,324 million (plus 12.1 percent / Fx & portfolio adj. plus 2.7 percent) / EBITDA before special items advances by 18.2 percent to EUR 10,266 million / EBIT improves by 15.8 percent to EUR 6,250 million / Net income increases 20.0 percent to EUR 4,110 million / Core earnings per share up 16.0 percent to EUR 6.83 / Forecast for 2016: further growth in sales and earningsLeverkusen, February 25, 2016 - The Bayer Group had a very successful year in
2015, both strategically and operationally. "Operationally it was another
record year for Bayer. Sales reached the highest level in the company's
history, exceeding EUR 46 billion. Clean EBITDA substantially rose by about 18
percent and also set a new record of more than EUR 10 billion," Management
Board Chairman Dr. Marijn Dekkers said on Thursday at the Financial News
Conference in Leverkusen. "Strategically we have taken all the necessary steps
to make Bayer a pure Life Science company," said Dekkers. The Bayer CEO
explained that the company had floated the former MaterialScience subgroup on
the stock market under the name Covestro and implemented a reorganization to
set the course for Bayer's successful further development. Dekkers forecasted
further growth in sales and earnings in 2016.
Group sales advanced by 12.1 percent to EUR 46,324 million (2014: EUR 41,339
million). After adjusting for currency and portfolio effects (Fx & portfolio
adj.), the increase was 2.7 percent. EBITDA before special items increased by
18.2 percent to EUR 10,266 million (2014: EUR 8,685 million). The good business
development was accompanied by higher R&D expenses (a year-on-year increase of
around EUR 740 million). Positive currency effects buoyed earnings by about EUR
680 million. EBIT increased by 15.8 percent to EUR 6,250 million (2014: EUR
5,395 million) after net special charges of EUR 819 million (2014: EUR 438
million). The special charges mainly comprised expenses for the consolidation
of production sites, integration costs for acquired businesses and expenses
connected with the carve-out and stock market flotation of Covestro. A special
gain from a litigation in connection with a breach of contract and patent
infringement had a positive effect. Net income climbed by 20.0 percent to EUR
4,110 million (2014: EUR 3,426 million), and core earnings per share from
continuing operations by 16.0 percent to EUR 6.83 (2014: EUR 5.89).
Gross cash flow from continuing operations rose by 4.4 percent to EUR 6,999
million (2014: EUR 6,707 million) and was thus substantially above the gross
cash flow hurdle of approximately EUR 5.7 billion. "In 2015, Bayer far exceeded
the minimum return and reproduction requirements and thus created value. All
subgroups contributed to this performance," stressed Chief Financial Officer
Johannes Dietsch. Net cash flow (total) rose by 18.6 percent to EUR 6,890
million (2014: EUR 5,810 million). Net financial debt declined by EUR 2.2
billion between the end of 2014 and December 31, 2015, to EUR 17.4 billion.
Substantial sales and earnings growth at HealthCare
Sales of the HealthCare subgroup rose by 19.9 percent (Fx & portfolio adj. 8.1
percent) to EUR 22,874 million (2014: EUR 19,075 million). "This encouraging
growth was driven by the recently launched pharmaceutical products," explained
Dekkers. "Business also expanded in all divisions of the Consumer Health
segment." The considerable reported sales growth was chiefly attributable to
the products acquired from Merck & Co., Inc., United States, and to currency
Sales of the Pharmaceuticals segment climbed by a substantial 9.9 percent (Fx &
portfolio adj.) to EUR 13,745 million. The recently launched products - the
anticoagulant Xarelto™, the eye medicine Eylea™, the cancer drugs Stivarga™ and
Xofigo™, and Adempas™ to treat pulmonary hypertension - posted combined sales
of EUR 4,231 million (2014: EUR 2,908 million). Sales of Xarelto™ were up by a
significant 34.2 percent (Fx adj.), mainly as a result of expanded volumes in
Germany and Japan. A strong sales gain was also registered in the United
States, where Xarelto™ is marketed by a subsidiary of Johnson & Johnson.
Following its approval in additional indications, sales of Eylea™ posted even
more substantial growth of 57.4 percent (Fx adj.).
Among Bayer's established top products, the hormone-releasing intrauterine
devices of the Mirena™ product family and the cancer drug Nexavar™ in
particular were successful. Sales of these products rose by 5.7 and 7.4 percent
(Fx adj.), respectively. Increased competition caused sales of our multiple
sclerosis drug Betaferon™/Betaseron™ to decline by 8.1 percent (Fx adj.). In
addition, business with YAZ™/Yasmin™/Yasminelle™ oral contraceptives declined
by 4.7 percent (Fx adj.) due to generic competition in Europe and the United
States. Overall, the Pharmaceuticals business registered encouraging growth in
all regions on a currency-adjusted basis. Business developed especially well in
Germany, Japan and the United States.
Sales of the Consumer Health segment advanced by 5.1 percent (Fx and portfolio
adj.) to EUR 9,129 million. Consumer Care achieved sales of EUR 1,770 million
with the products acquired from Merck & Co., Inc., United States. The skincare
product Bepanthen™/ Bepanthol™ posted considerable growth of 11.5 percent (Fx
adj.). Business with the antifungal product Canesten™ showed pleasing
development in all regions (Fx adj. plus 17.3 percent). Sales of the analgesic
Aleve™ also developed positively (Fx adj. plus 4.8 percent), mainly because of
price and volume increases in Latin America/Africa/Middle East. In the Animal
Health Division, the Seresto™ flea and tick collar made a significant
contribution to sales growth. By contrast, sales of the Advantage™ family of
flea, tick and worm control products receded slightly (Fx adj. minus 1.3
percent). In the contrast agents and medical equipment business (Medical Care),
the MRI contrast agent Gadovist™/ Gadavist™ posted encouraging growth of 17.6
percent (Fx adj.).
EBITDA before special items of HealthCare rose by a substantial 19.8 percent to
EUR 6,419 million (2014: EUR 5,357 million). This earnings growth resulted
mainly from the very favorable development of business at Pharmaceuticals and
Consumer Health - at the latter especially due to the contributions from the
acquired businesses. There were also positive currency effects of about EUR 250
million. Earnings were diminished by increased research and development
spending at Pharmaceuticals and higher selling expenses at Consumer Health.
CropScience: good business development despite a weaker market environment
Sales of the agriculture business (CropScience) increased in 2015 by 9.2
percent (Fx & portfolio adj. 1.7 percent) to EUR 10,367 million (2014: EUR
9,494 million). "Despite a weaker market environment, sales at CropScience
increased further," stressed Dekkers. "We thus grew faster on average than our
most important competitors." Both Crop Protection/Seeds and Environmental
Science registered growth. In regional terms, business in Europe saw
particularly encouraging development. There, CropScience achieved a gain of 8.2
percent (Fx adj.). Sales rose by 1.3 percent (Fx adj.) in Asia/Pacific but
declined by 1.6 percent (Fx adj.) in North America. In Latin
America/Africa/Middle East, sales were level year on year (Fx adj. minus 0.5
Crop Protection posted gratifying sales gains at Fungicides (Fx & portfolio
adj. plus 9.5 percent) and Herbicides (Fx & portfolio adj. plus 5.4 percent)
but a substantial decline at Insecticides (Fx & portfolio adj. minus 14.0
percent) that was mainly attributable to lower pest pressure in Brazil. Sales
of SeedGrowth (seed treatments) fell by 10.6 percent (Fx and portfolio adj.).
At Seeds, sales improved by 8.8 percent (Fx & portfolio adj.) with soybeans and
canola seed developing particularly well. Business in Environmental Science
advanced by 4.1 percent (Fx & portfolio adj.).
EBITDA before special items of CropScience improved by 2.4 percent to EUR 2,416
million (2014: EUR 2,360 million). In addition to positive earnings effects due
to the satisfactory business development, including higher volumes and slightly
improved selling prices, there was a very positive currency effect of about EUR
220 million. On the other hand, there was an increase in the cost of goods sold
and in research and development expenses.
Covestro posts strong earnings improvement
Sales of the high-tech polymer materials business (Covestro, formerly
MaterialScience) moved forward by 2.8 percent to EUR 11,982 million (2014: EUR
11,651 million). Adjusted for currency and portfolio effects, sales declined by
5.1 percent as a result of lower selling prices in all business units. On the
other hand, Covestro expanded volumes in all business units. EBITDA before
special items improved by a marked 39.8 percent to EUR 1,659 million (2014: EUR
1,187 million). Considerably lower raw material prices more than offset the
decline in selling prices. Furthermore, earnings were buoyed by positive
currency effects of about EUR 240 million.
Bayer currently still holds a 69 percent interest in Covestro. As a fully
consolidated subsidiary, Covestro continues to be included in the Bayer Group
consolidated financial statements. In core earnings per share, however, 31
percent of Covestro earnings are attributable to external stockholders of
Covestro. This has the effect of diminishing Bayer's core earnings per share.
Sales of HealthCare and CropScience rise in the fourth quarter
Group sales rose by 4.9 percent (Fx & portfolio adj. 2.4 percent) in the fourth
quarter of 2015 to EUR 11,319 million (Q4 2014: EUR 10,792 million). HealthCare
and CropScience contributed to this performance, while sales were down at
Covestro. EBITDA before special items improved by 4.0 percent to EUR 1,903
million (Q4 2014: EUR 1,829 million). This good business development,
especially at HealthCare, was accompanied by higher R&D and selling expenses.
Positive currency effects contributed EUR 200 million to earnings. EBIT
improved by a significant 65.4 percent to EUR 908 million (Q4 2014: EUR 549
million). The increase in net income to EUR 613 million was even more
substantial (Q4 2014: plus EUR 224 million). Core earnings per share from
continuing operations fell to EUR 1.07 (Q4 2014: EUR 1.17), however. In the
previous year, they were influenced by tax income.
Bayer targeting further growth in 2016
Dekkers expressed his confidence for fiscal 2016: "We are targeting further
growth in both sales and earnings, building on a record year," said the
Management Board Chairman. This forecast is based on the new organizational
structure introduced with effect from January 1, 2016, and assumes the
full-year inclusion of the Covestro business. Also underlying the forecast for
fiscal 2016 are the exchange rates at the closing date on December 31, 2015,
including a rate of US$1.09 to the euro.
In 2016, the Bayer Group including Covestro is planning sales of more than EUR
47 billion. This corresponds to a low-single-digit percentage increase on a
currency- and portfolio-adjusted basis. Bayer plans to increase EBITDA before
special items by a mid-single-digit percentage. The company aims to increase
core earnings per share from continuing operations by a mid-single-digit
percentage as well. This assumption takes account of the fact that only 69
percent of Covestro will be reflected for the full year 2016. From the sale of
the Diabetes Care business, Bayer expects core earnings per share of just under
EUR 0.40 for discontinued operations.
Sales of approximately EUR 35 billion are planned for the Life Science
activities, i.e. the Bayer Group excluding Covestro (2015 pro forma: EUR 34,342
million). This corresponds to a mid-single-digit percentage increase on a
currency- and portfolio-adjusted basis. Bayer also plans to increase EBITDA
before special items by a mid-single-digit percentage (2015 pro forma: EUR
8,607 million). This planning includes dissynergies of around EUR 130 million
from the carve-out of Covestro and from divestments.
Despite declining price developments in some areas, Bayer expects sales of
approximately EUR 16 billion (2015 pro forma: EUR 15,308 million) in the
Pharmaceuticals Division including the Radiology business. This corresponds to
a mid-single-digit percentage increase on a currency- and portfolio-adjusted
basis. The company plans to raise sales of the recently launched pharmaceutical
products to more than EUR 5 billion. It expects a mid- to high-single-digit
percentage increase in EBITDA before special items (2015 pro forma: EUR 4,615
million). Bayer aims to improve the EBITDA margin before special items.
In the Consumer Health Division, Bayer expects sales to come in at more than
EUR 6 billion and plans to grow sales by a mid-single-digit percentage on a
currency- and portfolio-adjusted basis (2015 pro forma: EUR 6,076 million).
EBITDA before special items is also expected to improve by a mid-single-digit
percentage (2015 pro forma: EUR 1,456 million).
At Crop Science, Bayer expects sales to be at the prior-year level (2015: EUR
10,367 million). This corresponds to a low-single-digit percentage increase on
a currency- and portfolio-adjusted basis. For this division, Bayer plans to
increase EBITDA before special items by a low-single-digit percentage (2015:
EUR 2,416 million).
At Animal Health, Bayer expects sales slightly above the prior-year level
(2015: EUR 1,490 million). This corresponds to a low- to mid-single-digit
percentage increase on a currency- and portfolio-adjusted basis. For this
business, Bayer also plans an increase in EBITDA before special items by a low-
to mid-single-digit percentage (2015 pro forma: EUR 348 million).
For 2016, Covestro is budgeting sales at the prior-year level and a decline in
EBITDA after adjustment for special items.
Bayer expects to take special charges in the region of EUR 0.5 billion in 2016,
with the integration of the acquired consumer health businesses and charges in
connection with the reorganization of the Bayer Group accounting for most of
this amount. Bayer intends to increase research and development spending in
2016 to approximately EUR 4.5 billion. The company has budgeted capital
expenditures of about EUR 2.5 billion for property, plant and equipment and EUR
0.4 billion for intangible assets. Depreciation and amortization are estimated
at about EUR 3.1 billion, including EUR 1.6 billion in amortization of
intangible assets. Bayer expects net financial debt to be below EUR 16 billion
at the end of 2016.
Dekkers: Europe must become more innovative
Dekkers emphasized at the Financial News Conference that innovation is the
foundation of Bayer's commercial success. The company employs nearly 15,000
people worldwide in research and development and increased its R&D spending
last year by 21.0 percent to EUR 4,281 million. "However, we need an
environment that supports our innovation efforts if we are to fully exhaust our
potential. I am firmly convinced that Europe must become more innovative," said
In the first place, the Bayer CEO sees a need for action in the sociocultural
environment. "While everyone is in favor of innovation in theory, concerns
quickly gain the upper hand when it comes to specific technologies." Dekkers
accepted that it's right to openly discuss new technologies. However, this
debate should be based on scientific facts. Dekkers therefore called on
science, politics and industry to strengthen their engagement in public debate.
Secondly, it is important to support technological advances with appropriate
regulations, rather than to hinder them. "I'm therefore very much in favor of
introducing a European innovation principle - a kind of innovation inspection
to examine the effects that regulations would have on industry's innovation
strength," Dekkers said. This could meaningfully supplement the European
precautionary principle, he explained. Taken together, the two principles could
ensure a more balanced assessment of the benefits and risks of new
technologies, remarked the Bayer CEO, adding that this would make it possible
to improve regulations - and increase innovation.
"We must also improve the external financing conditions for innovation in order
to become more innovative," Dekkers continued. The Management Board Chairman
explained that Germany needs a venture capital law that gives young companies
easier access to start-up capital.
Below you will find tables containing the key data of the Bayer Group and its
subgroups for the full year and the fourth quarter of 2015.
The complete Annual Report 2015 is available on the Internet at
Supplementary material at www.investor.bayer.com includes:
- Live webcast of the Financial News Conference from approx. 10:00 a.m. CET
- Presentation charts for the Investor Conference Call at 12:00 noon CET
- Live webcast of the Investor Conference Call from approx. 2:00 p.m. CET
- Recording of the Investor Conference Call from approx. 6:00 p.m. CET